Good news, but not surprising insofar as most of the patients in the phase-2a NIH trial used a smaller daily dose of OCR-002 than is being used in OCRX's own STOP-HE trial.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.